DECEMBER 22, 2011 - This projection by the Toronto-based Millennium Research Group (MRG) says some doctors report they lack confidence in the current urogynecologic surgical mesh products. Sales have been flat in 2011 partially due to patients speaking out about adverse events (see Patient Profiles here), two warnings about complications from the Food and Drug Administration, and an advisory committee that is urging the approval process be made stronger.
However the MRG analyst, Sohaib Perwaiz, projects that transvaginal pelvic floor repair (PFR) procedures “and sacral colpopexy/hysteropexy procedures using either a synthetic mesh or biologic graft will increase by 2 percent” says the news release (here) issued December 22.
The analyst believes some brands of mesh have been more successful than others measured in part by physician loyalty, name brand, mesh material and weight, training programs, and patient profiles.
MRG has issued a report, Urogynecologic Surgical Mesh: Controversies in Pelvic Organ Prolapse and Stress Urinary Incontinence Treatment, which is proprietary and available only by purchase. MDND has a call into the analyst at this time for a summary.
The news release says it contains information about future clinical applications for synthetic and biologic surgical mesh and suburethral slings as well as the doctor perceptions of the products.
More information at :
Millennium Research Group
Alex Jablokow, 617-599-8613, email@example.com